secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-104092
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q2 revenue $264.6M (+9% YoY); NUPLAZID guidance raised to $665-690M
--------------------------------------------------------------------------

- Total revenue $264.6M, NUPLAZID $168.5M (+7%), DAYBUE $96.1M (+14%).
- Net income $26.7M ($0.16 EPS) vs $33.4M ($0.20 EPS) YoY due to higher tax rate.
- Raised NUPLAZID net sales guidance low end to $665M; total revenue guidance $1.045-1.095B.
- Patent litigation wins affirm NUPLAZID exclusivity through 2030 (composition) and 2038 (formulation).
- COMPASS PWS Phase 3 study enrollment complete; top-line results expected early Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017025104092/0000950170-25-104092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017025104092/acad-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer